Pyoderma gangrenosum
Pyoderma gangrenosum je zriedkavé zápalové ochorenie kože, pri ktorom sa bolestivé pustuly alebo uzliny menia na vredy, ktoré postupne rastú. Pyoderma gangrenosum nie je infekčné. Liečba môže zahŕňať kortikosteroidy, cyklosporín alebo rôzne monoklonálne protilátky. Hoci môže postihnúť ľudí v akomkoľvek veku, najčastejšie postihuje osoby vo veku 40 až 50 rokov.
☆ AI Dermatology — Free Service
Vo výsledkoch Stiftung Warentest z Nemecka za rok 2022 bola spokojnosť spotrebiteľov s ModelDerm len o niečo nižšia ako s platenými telemedicínskymi konzultáciami.
Vo výsledkoch Stiftung Warentest z Nemecka za rok 2022 bola spokojnosť spotrebiteľov s ModelDerm len o niečo nižšia ako s platenými telemedicínskymi konzultáciami.
Na nohe osoby trpiacej ulceróznou kolitídou.
relevance score : -100.0%
ReferencesPyoderma gangrenosum je zriedkavé ochorenie kože, ktoré spôsobuje bolestivé vredy s červenými alebo purpurovými okrajmi. Je klasifikované ako zápalové ochorenie a patrí do skupiny nazývanej neutrofilné dermatózy. Príčina pyoderma gangrenosum je komplexná a zahŕňa poruchy vrodeného i adaptívneho imunitného systému u ľudí s genetickou predispozíciou. Nedávno sa vedci zamerali na vlasový folikul ako potenciálny spúšťací bod ochorenia.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum je zriedkavé kožné ochorenie spôsobujúce extrémne bolestivé vredy. Aj keď úplne nerozumieme príčine ochorenia, vieme, že zahŕňa zvýšenú aktivitu určitých imunitných buniek. Liečba tohto ochorenia stále nie je jednoduchá. K dispozícii máme rôzne lieky, ktoré potláčajú imunitný systém alebo upravujú jeho činnosť. Okrem toho sa zameriavame aj na ošetrovanie rán a zvládanie bolesti. Kortikosteroidy a cyklosporín sú často prvou voľbou liečby, avšak v poslednej dobe sa čoraz viac skúma použitie biologických terapií, napríklad inhibítorov TNF‑α. Tieto biologické lieky sú čoraz častejšie uprednostňované, najmä u pacientov s inými zápalovými ochoreniami, a používajú sa skôr v neskorších štádiách ochorenia.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
